Congress orders investigation into health insurers' anti-competitive contract tactics

What it does

This bill directs the Government Accountability Office (GAO), working with the Federal Trade Commission and Department of Justice, to study anti-competitive contract clauses used between health insurers and providers—including clauses that prevent insurers from steering patients to cheaper competitors, requiring all-or-nothing provider inclusion, restricting tiered pricing, or hiding price information. The study will assess whether these clauses harm competition, raise consumer costs, and limit access, and will recommend whether new laws or enforcement resources are needed.

Why we flagged it

The bill's sole mechanism is a mandated study of anti-competitive contracting practices in health insurance. It does not itself regulate or ban any clauses; it gathers evidence and recommends future action. This is investigative/informational legislation, not a direct regulatory intervention.

What the text implies

• Study findings may trigger enforcement actions by FTC/DOJ without additional legislation, potentially disrupting existing insurer-provider contracts and reshaping network structures.
• Recommendations for 'legislative or administrative actions' could lead to follow-on bills that directly restrict or ban named contract clauses, fundamentally altering health insurance market dynamics.
• Gag-clause transparency provisions (if adopted) would expose negotiated rates and discounts currently kept confidential, potentially destabilizing price negotiations and enabling provider-to-provider rate comparison.
• Study may reveal enforcement resource gaps, leading to budget increases for antitrust agencies and expanded regulatory scrutiny of health care consolidation.

Who it affects

The bill creates transparency and investigative capacity around contractual practices that may artificially inflate health care costs and limit consumer choice. A study identifying anti-competitive clauses and enforcement gaps could lead to policy changes that lower prices and expand access—direct benefits to patients and the general public.

Who stands to gain

• smaller health care providers and independent practices (may benefit from reduced anti-competitive c
• consumers (lower health care costs if anti-competitive practices are curtailed)
• potential beneficiaries of enforcement: FTC and DOJ (expanded budgets and authority)

Named in the bill

Government Accountability Office (GAO), Federal Trade Commission (FTC), Department of Justice (DOJ), Antitrust Division, Health insurers, Health care providers, Hospital systems, Health plan administrators

Where it stands

• Apr 24, 2025 — Introduced · Congress.gov: “Introduced in House”
• Apr 24, 2025 — Referred to House Committee on the Judiciary and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 2 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $3,720,000 in lobbying spend. A filing names 47 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

Victoria Spartz, the sponsor, reported $117,000 in PAC receipts in the 2026 cycle.

• America's Health Insurance Plans Inc (ahip) — $3,010,000 on 1 filing
• Federation of American Hospitals — $710,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.